Compare Nucor Corporation (NUE) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Novartis AG — how do they compare? Nucor Corporation trades at $248 (market cap $55.91B), while Novartis AG trades at $142.74 (market cap $274.00B). The key difference: Novartis AG is far larger — about 4.9× Nucor Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Novartis AG for 82 Days on average.
| NUE | NVS | |
|---|---|---|
Market Cap | $55.91B | $274.00B |
Volume | 1,062,743 | 1,852,137 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $168.62 |
52-Week Low | $131.78 | $121.80 |
Typical Hold Time | 78 Days | 82 Days |
Enterprise Value | $60.32B | $315.32B |
Dividend Yield | 0.91% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 1.96% on the day, amid a neutral technical signal with mixed moving averages and oscillators. Recent earnings show Q1 and Q2 2026 beats, but Q3 guidance of $5.75 EPS is pending. Revenue for 2025 was $32.49B with a net income margin of 7.99%, while 2026 projections indicate a rebound to $36.1B revenue and 7.98% margin. The company maintains a strong balance sheet with $4.14B cash and a debt-to-asset ratio of 20.23% for 2025.
Outlook remains cautiously optimistic with a consensus price target of $266.88, implying ~8% upside, supported by 57.58% analyst buy ratings. Risks include competitive pressures from a new $15B Iowa steel mill and volatile steel prices, but Nucor's low-cost operations and dividend consistency (214th consecutive payout) provide stability. Investors should monitor Q3 earnings for confirmation of growth trajectory amid sector headwinds.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
